NCT04262544

Brief Summary

Heart failure (HF) is associated with high mortality and hospitalization rates. Prior studies show that adherence to routine HF self-care behaviors reduces the risk of all-cause mortality and HF-related hospitalizations, and improves health related quality of life. However, self-care has generally been found to be poor among HF patients. This study aims to assess the feasibility, acceptance, and efficacy of an innovative, patient-centered intervention (iCardia4HF) that aims to promote adherence to HF self-care and improve patient outcomes through the use of commercially available mobile health technologies.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
89

participants targeted

Target at P50-P75 for not_applicable heart-failure

Timeline
Completed

Started Feb 2020

Typical duration for not_applicable heart-failure

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 6, 2020

Completed
1 month until next milestone

First Posted

Study publicly available on registry

February 10, 2020

Completed
10 days until next milestone

Study Start

First participant enrolled

February 20, 2020

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2022

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2022

Completed
Last Updated

April 28, 2023

Status Verified

April 1, 2023

Enrollment Period

2.6 years

First QC Date

January 6, 2020

Last Update Submit

April 27, 2023

Conditions

Keywords

mHealthtext messagingsmartphonemobile appswearablesheart failureself-managementtelehealth

Outcome Measures

Primary Outcomes (3)

  • Medication adherence (dose count)

    Percent of prescribed number of doses taken

    Weeks 1 to 12

  • Medication adherence (dose time)

    Percent of doses taken on schedule within 25% of the expected time interval

    Weeks 1 to 12

  • Adherence to daily self-monitoring of weight

    Number of days patients completed at least one measurement between 12 am and 11:59pm

    Weeks 1 to 12

Secondary Outcomes (11)

  • Adherence to daily self-monitoring of blood pressure

    Weeks 1 to 12

  • Adherence to self-monitoring of HF symptoms

    Weeks 1 to 12

  • Physical activity - Steps

    Weeks 1 to 12

  • Moderate-to-Vigorous Physical Activity

    Weeks 1 to 12

  • Adherence to low-sodium diet

    Baseline, 12 Weeks

  • +6 more secondary outcomes

Other Outcomes (6)

  • HF-related hospitalizations

    Weeks 1 to 12

  • HF-related hospitalization rate

    Weeks 1 to 12

  • All-cause hospitalizations

    Weeks 1 to 12

  • +3 more other outcomes

Study Arms (2)

mHealth

EXPERIMENTAL

Intervention group

Behavioral: iCardia4HF

Usual Care

ACTIVE COMPARATOR

Control group

Other: Usual Care

Interventions

iCardia4HFBEHAVIORAL

Participants in the intervention group will receive the following main components in addition to usual care: 1) the Heart Failure Health Storylines mobile app which supports daily self-monitoring and management of vital signs and symptoms; 2) three connected health devices (Fitbit activity tracker, Withings Cardio Body weight scale and blood pressure monitor), and 3) a program of tailored text-messages targeting health beliefs, self-efficacy, and HF-knowledge.

mHealth

Participants assigned to the control group will receive usual care and the same connected health devices (Fitbit activity tracker, Withings weight scale and blood pressure monitor) as patients in the intervention group, but without the heart failure health storylines mobile app and text-messaging program. Usual care includes patient education before hospital discharge, and follow-up visits at the outpatient HF clinic a week after discharge and monthly thereafter depending on the patient's condition. Patient education includes literacy-sensitive, education material about HF self-care developed by the Sheps Center for Health Services Research,and a 40-minute education session with an APN and a dietician to review and discuss the education material provided to the patient.

Usual Care

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Chronic HF, Stage C
  • ≥ 18 years of age
  • Being treated with oral diuretics for heart failure
  • Suboptimal HF self-care adherence (score 1 or 2 in at least two items of the Self-care of Heart Failure Index v.7.2)
  • Ability to speak and read English

You may not qualify if:

  • Planned coronary revascularization, Transcatheter Aortic Valve Implantation (TAVI), Cardiac Resynchronization Therapy (CRT) - implantation, and/or heart transplantation (HTx) within the next 3 months.
  • Coronary revascularization and/or CRT-implantation within the last 30 days
  • Advanced renal disease (stage IV CKD, GFR\<30, or hemodialysis)
  • Known alcohol or drug use
  • End-stage HF (hospice candidate)
  • Active cancer
  • Pregnancy
  • Not able to take care of self (eat, dress, walk, bath, take medications, or use the toilet)
  • Discharged to or already living in a nursing home or other care facility other than home
  • Cognitive impairment (MoCA score \< 22).
  • Prior use of study devices for self-care or participation in a similar trial

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Illinois Hospital & Health Sciences System

Chicago, Illinois, 60612, United States

Location

Related Publications (1)

  • Kitsiou S, Gerber BS, Kansal MM, Buchholz SW, Chen J, Ruppar T, Arrington J, Owoyemi A, Leigh J, Pressler SJ. Patient-centered mobile health technology intervention to improve self-care in patients with chronic heart failure: Protocol for a feasibility randomized controlled trial. Contemp Clin Trials. 2021 Jul;106:106433. doi: 10.1016/j.cct.2021.106433. Epub 2021 May 13.

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Study Officials

  • Spyros Kitsiou

    University of Illinois at Chicago

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
CARE PROVIDER, OUTCOMES ASSESSOR
Masking Details
Care providers (doctors and nurses) providing usual care to study participants will be blinded to the allocation of participants. Data collectors and assessors of subjective outcomes (e.g. health beliefs, self-efficacy, self-care) will be blinded to the allocation. Study participants will be asked not to reveal to their provider and assessor which group they are assigned to. Data collectors/assessors will have restricted access to patient data in REDCap and will not share the same space with other study investigators.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

January 6, 2020

First Posted

February 10, 2020

Study Start

February 20, 2020

Primary Completion

September 30, 2022

Study Completion

December 31, 2022

Last Updated

April 28, 2023

Record last verified: 2023-04

Data Sharing

IPD Sharing
Will share

Final research data along with metadata and descriptors will be shared to make sharing meaningful and usable by other researchers. More specifically, we will share both de-identified individual-level data and aggregate data in the form of summary statistics and tables. For the individual-level data, we will develop a data dictionary and documentation guide to maximize the utility of the data and to help qualified researchers understand and properly use the data as needed.

Shared Documents
STUDY PROTOCOL, CSR
Time Frame
Within 2 years after the final data collection is completed or within one year after the publication of the main outcomes manuscript (whichever comes first), we will share the final, completely de-identified dataset with the research community.

Locations